Hub : Traits :

Qualifications: None of the above

726 significantly associated models · 136 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	43073464	45157738	12	3	2.0e-13	2.2e-15	3.1e-01	98	MED8 RP11-7O11.3 ST3GAL3
2	1	71163715	73435171	1	1	4.8e-10	4.2e-09	4.0e-04	64	NEGR1
3	1	92957826	94426916	3	1	1.4e-09	2.9e-07	8.8e-01	100	TMED5
4	1	109316076	110716511	1	1	6.3e-08	7.4e-07	4.5e-02	84	SYPL2
5	2	43899918	45698128	1	1	3.6e-09	8.4e-10	4.7e-02	90	CAMKMT
6	2	99922967	101731705	3	1	6.8e-09	6.5e-09	1.4e-01	93	CHST10
7	2	106725928	108199394	1	1	1.2e-07	1.9e-07	1.0e+00	100	ST6GAL2
8	3	16154636	17814553	1	1	2.2e-08	2.7e-09	1.8e-02	84	PLCL2
9	3	48268509	51009435	26	2	2.2e-15	2.1e-13	1.2e-01	96	GPX1 RBM6
10	3	52047421	53860103	3	1	1.7e-07	3.5e-08	8.0e-02	90	NEK4
11	3	107181540	108633112	1	1	1.0e-07	2.0e-06	1.4e-01	90	IFT57
12	3	124558741	125238099	1	1	1.9e-07	7.7e-08	1.4e-01	92	SLC12A8
13	4	2233366	3740612	2	1	2.7e-07	5.6e-08	3.7e-07	12	MFSD10
14	4	105598022	107092169	1	1	3.0e-09	3.2e-09	1.3e-02	82	PPA2
15	5	26181001	27729100	1	1	2.2e-07	6.9e-09	2.3e-04	60	CDH9
16	5	59193824	61156570	5	2	1.9e-17	3.2e-17	7.0e-01	100	ELOVL7
17	5	87006055	88875673	2	2	4.5e-10	7.9e-17	2.0e-08	55	CTC-498M16.2 MEF2C
18	5	176132977	177591495	3	1	5.9e-09	1.0e-08	1.0e+00	100	DBN1
19	6	87530372	88997402	1	1	2.8e-08	2.4e-08	1.0e+00	100	RARS2
20	7	23913624	25432157	1	1	3.5e-08	2.2e-08	1.0e+00	100	MPP6
21	8	30012514	31433801	1	1	1.8e-07	9.3e-08	1.0e-01	91	TEX15
22	8	142629143	144515639	2	3	2.2e-10	6.9e-11	4.9e-03	81	THEM6 TSNARE1
23	9	111008699	112472083	1	1	2.5e-07	2.2e-06	3.3e-02	80	CTNNAL1
24	10	10349662	12076043	1	1	1.6e-08	7.7e-08	1.0e-02	77	CELF2
25	10	64195778	65911294	4	1	3.4e-15	1.6e-15	1.1e-03	83	NRBF2
26	10	102853189	104242886	2	1	2.6e-08	1.0e-08	1.5e-03	69	NPM3
27	10	133048749	134482926	2	2	7.8e-10	2.2e-12	8.7e-01	100	BNIP3 PPP2R2D
28	11	94805896	96276010	4	1	1.9e-13	2.9e-13	2.2e-01	97	AP001877.1
29	11	116805204	117308936	1	1	6.5e-08	1.2e-04	6.5e-01	99	SIDT2
30	12	49556303	50927881	1	1	4.7e-08	4.9e-05	3.0e-02	71	BCDIN3D
31	12	55677395	57125879	5	1	5.4e-11	1.9e-10	1.0e+00	100	SUOX
32	12	122258047	124591385	13	2	1.4e-13	6.2e-12	6.6e-01	100	CDK2AP1 RSRC2
33	13	31078511	32595740	1	1	2.2e-07	1.7e-06	1.8e-01	92	B3GALTL
34	14	73853137	75366447	1	1	5.6e-08	3.0e-06	8.3e-04	49	LIN52
35	16	86671	1432491	1	1	1.4e-07	1.0e-06	7.4e-01	100	WDR24
36	16	24614505	25167985	1	1	1.5e-07	9.1e-09	1.6e-03	70	SLC5A11
37	16	27655848	29595483	19	1	3.6e-10	8.8e-10	5.3e-01	99	SULT1A1
38	16	52828325	54235440	2	1	2.5e-08	6.7e-09	8.6e-02	91	RBL2
39	17	34815551	35675511	1	1	1.5e-07	1.3e-06	5.4e-04	49	CTB-75G16.3
40	19	45064435	46506809	2	1	1.3e-11	1.5e-11	1.0e+00	100	CKM

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Qualifications: College or University degree	12.87	39	32	71.1	-0.98	7.4e-29	AP001877.1 B3GALTL BCDIN3D BNIP3 CAMKMT CDH9 CDK2AP1 CELF2 CHST10 CKM CTB-75G16.3 CTC-498M16.2 DBN1 ELOVL7 GPX1 IFT57 MED8 MFSD10 MPP6 NEGR1 NPM3 NRBF2 PPA2 PPP2R2D RARS2 RBL2 RBM6 RP11-7O11.3 RSRC2 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX TEX15 THEM6 TMED5 TSNARE1 WDR24
Qualifications: A levels/AS levels or equivalent	10.38	30	16	35.6	-0.99	1.0e-24	AP001877.1 CAMKMT CDH9 CDK2AP1 CELF2 CHST10 CKM DBN1 ELOVL7 GPX1 IFT57 MED8 MPP6 NEGR1 NPM3 NRBF2 PLCL2 PPA2 RBL2 RBM6 RP11-7O11.3 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX THEM6 TMED5 TSNARE1 WDR24
Intelligence (Savage-Jansen 2018)	8.44	29	16	35.6	-0.95	1.9e-16	AP001877.1 BNIP3 CAMKMT CDH9 CDK2AP1 CHST10 CKM CTB-75G16.3 DBN1 ELOVL7 GPX1 IFT57 MED8 NEGR1 NPM3 NRBF2 PLCL2 PPA2 PPP2R2D RBL2 RBM6 RP11-7O11.3 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX TEX15 TSNARE1
Fluid intelligence score	8.15	26	11	24.4	-0.98	4.1e-19	BNIP3 CAMKMT CDH9 CDK2AP1 CELF2 CHST10 CKM CTB-75G16.3 GPX1 IFT57 MED8 NEGR1 NPM3 NRBF2 PLCL2 PPA2 RBL2 RBM6 RP11-7O11.3 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX TEX15 TSNARE1
Qualifications: O levels/GCSEs or equivalent	7.86	18	3	6.7	-0.98	8.3e-13	AP001877.1 CAMKMT CDK2AP1 CKM CTB-75G16.3 ELOVL7 GPX1 IFT57 MFSD10 MPP6 NRBF2 PLCL2 PPP2R2D RP11-7O11.3 ST3GAL3 ST6GAL2 THEM6 TSNARE1
Verbal and Numeric Reasoning (VNR)	7.64	22	11	24.4	-0.97	6.9e-14	CDH9 CHST10 CKM CTB-75G16.3 DBN1 ELOVL7 GPX1 IFT57 NEGR1 NPM3 NRBF2 PLCL2 PPA2 RBL2 RBM6 SLC5A11 ST3GAL3 ST6GAL2 SULT1A1 SUOX TEX15 TSNARE1
Qualifications: nursing, teaching	7.18	9	3	6.7	-0.99	1.3e-07	B3GALTL CDK2AP1 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RP11-7O11.3 ST3GAL3
Age at first live birth	5.79	7	2	4.4	-0.96	5.0e-04	AP001877.1 GPX1 NRBF2 RBM6 RP11-7O11.3 SUOX WDR24
Overall health rating	5.53	12	7	15.6	0.97	1.2e-07	B3GALTL CKM GPX1 MFSD10 NRBF2 PPP2R2D RBL2 RBM6 SLC5A11 TEX15 THEM6 TSNARE1
Leg fat percentage (left)	5.30	20	11	24.4	0.78	5.6e-05	BNIP3 CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 NRBF2 RBM6 RSRC2 SIDT2 SLC5A11 SULT1A1 TEX15 THEM6 TSNARE1 WDR24
Leg fat percentage (right)	5.28	20	10	22.2	0.78	5.6e-05	BNIP3 CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 NRBF2 RBM6 RSRC2 SIDT2 SLC5A11 SULT1A1 TEX15 THEM6 TSNARE1 WDR24
Average weekly red wine intake	5.10	7	2	4.4	-0.98	7.1e-05	AP001877.1 CAMKMT CDK2AP1 CTC-498M16.2 NRBF2 RBM6 RP11-7O11.3
Alcohol usually taken with meals	5.07	5	1	2.2	-0.98	8.6e-04	CHST10 ELOVL7 MED8 NEGR1 NRBF2
Leg fat mass (left)	4.88	16	10	22.2	0.71	2.1e-03	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Leg fat mass (right)	4.85	16	10	22.2	0.71	2.1e-03	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Body mass index (BMI)	4.76	19	11	24.4	0.76	1.5e-04	CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MEF2C MFSD10 MPP6 NEGR1 NEK4 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
BMI	4.68	18	15	33.3	0.70	1.2e-03	CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MEF2C MFSD10 NEGR1 NEK4 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Smoking Status	4.36	15	6	13.3	0.97	1.5e-09	CELF2 CKM ELOVL7 GPX1 IFT57 MED8 MEF2C MFSD10 NEK4 PLCL2 RBM6 RP11-7O11.3 SLC5A11 SUOX WDR24
Age at last live birth	4.35	3	2	4.4	0.00	1.0e+00	AP001877.1 GPX1 RBM6
Arm fat mass (right)	4.25	14	9	20.0	0.67	9.2e-03	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Alcohol intake frequency.	4.16	10	3	6.7	0.80	6.0e-03	B3GALTL BNIP3 CDK2AP1 CTC-498M16.2 NEGR1 RBM6 SULT1A1 TEX15 TSNARE1 WDR24
Arm fat mass (left)	4.13	14	9	20.0	0.67	9.0e-03	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Whole body fat mass	4.06	14	9	20.0	0.65	1.1e-02	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Body fat percentage	4.02	15	9	20.0	0.69	4.1e-03	CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SIDT2 SLC5A11 SULT1A1 TEX15 THEM6
Waist circumference	3.94	15	8	17.8	0.72	2.6e-03	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 NEGR1 NRBF2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Arm fat percentage (right)	3.92	14	8	17.8	0.68	7.7e-03	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Age at First Birth	3.89	3	2	4.4	0.00	1.0e+00	CHST10 GPX1 RBM6
Arm fat percentage (left)	3.80	15	7	15.6	0.68	5.7e-03	CAMKMT CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Mouth/teeth dental problems: Dentures	3.75	4	1	2.2	0.99	9.5e-03	BCDIN3D GPX1 RBM6 TMED5
Maternal smoking around birth	3.69	4	1	2.2	-0.46	5.4e-01	CKM CTB-75G16.3 MED8 SLC5A11
Fed-up feelings	3.67	8	1	2.2	0.98	9.1e-06	B3GALTL CDK2AP1 GPX1 PLCL2 RBM6 SLC5A11 TEX15 THEM6
Average weekly champagne plus white wine intake	3.63	2	0	0.0	0.00	1.0e+00	SULT1A1 WDR24
Current tobacco smoking	3.59	1	0	0.0	0.00	1.0e+00	SLC5A11
Weight	3.54	14	10	22.2	0.44	1.1e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 GPX1 IFT57 NEGR1 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX TEX15 THEM6
Blood Platelet Count	3.53	8	6	13.3	-0.25	5.6e-01	CDK2AP1 CKM MEF2C MPP6 NRBF2 SIDT2 TMED5 WDR24
Alcohol intake versus 10 years previously	3.48	3	0	0.0	0.00	1.0e+00	GPX1 NEGR1 RP11-7O11.3
Trunk fat mass	3.47	11	9	20.0	0.57	7.0e-02	CHST10 CTB-75G16.3 CTC-498M16.2 GPX1 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Miserableness	3.38	4	3	6.7	1.00	3.9e-03	B3GALTL CELF2 GPX1 RBM6
Trunk fat percentage	3.32	12	7	15.6	0.64	2.4e-02	CHST10 CTB-75G16.3 GPX1 MFSD10 MPP6 NEGR1 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Depressed Affect (Nagel 2018)	3.30	5	2	4.4	0.70	1.9e-01	CDH9 CELF2 GPX1 PLCL2 RBM6
Pack years adult smoking proportion	3.26	4	0	0.0	0.23	7.7e-01	BNIP3 GPX1 MFSD10 NRBF2
Hip circumference	3.24	12	8	17.8	0.27	4.0e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 GPX1 NEGR1 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 TEX15 THEM6
Triglycerides	3.21	2	2	4.4	0.00	1.0e+00	NRBF2 SIDT2
Unable to work because of sickness or disability	3.20	2	0	0.0	0.00	1.0e+00	ELOVL7 SLC5A11
Comparative body size at age 10	3.14	7	4	8.9	0.03	9.5e-01	BCDIN3D CTB-75G16.3 CTC-498M16.2 MEF2C NEGR1 RBM6 SULT1A1
Number of treatments/medications taken	3.12	6	2	4.4	0.75	8.8e-02	B3GALTL GPX1 NEGR1 PPP2R2D RBM6 ST6GAL2
Frequency of unenthusiasm / disinterest in last 2 weeks	3.09	1	0	0.0	0.00	1.0e+00	GPX1
Impedance of arm (left)	3.08	10	7	15.6	-0.74	1.5e-02	CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 NEK4 NRBF2 RBM6 SUOX
Impedance of arm (right)	3.07	10	8	17.8	-0.47	1.4e-01	CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 NEK4 NRBF2 RBM6 SUOX SYPL2
Average weekly beer plus cider intake	3.04	2	0	0.0	0.00	1.0e+00	NRBF2 RBM6
Body Mass Index (BMI) (2010)	3.01	3	2	4.4	0.00	1.0e+00	CTB-75G16.3 NEGR1 SULT1A1
Exposure to tobacco smoke outside home	3.00	2	0	0.0	0.00	1.0e+00	ELOVL7 RBM6
Pack years of smoking	2.93	2	0	0.0	0.00	1.0e+00	GPX1 MFSD10
Arm predicted mass (left)	2.89	14	12	26.7	0.15	6.0e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Pain experienced in last month	2.88	3	1	2.2	0.00	1.0e+00	GPX1 RBM6 SUOX
Mood swings	2.87	5	1	2.2	0.99	1.1e-03	CELF2 GPX1 PLCL2 RBM6 SLC5A11
Arm fat-free mass (left)	2.85	14	11	24.4	0.14	6.2e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Major Depression (MDD)	2.83	2	1	2.2	0.00	1.0e+00	GPX1 NEGR1
Commuting to job workplace: Public transport	2.83	2	0	0.0	0.00	1.0e+00	CHST10 NEGR1
Impedance of whole body	2.83	13	9	20.0	-0.41	1.5e-01	CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 MEF2C NEGR1 NEK4 NRBF2 PPA2 RBM6 SUOX SYPL2
Townsend deprivation index at recruitment	2.82	1	0	0.0	0.00	1.0e+00	CKM
Basal metabolic rate	2.81	15	11	24.4	0.11	6.8e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Diastolic blood pressure, automated reading	2.81	9	5	11.1	0.70	3.5e-02	CDK2AP1 GPX1 MED8 MPP6 NRBF2 SLC5A11 ST6GAL2 THEM6 TSNARE1
Systolic blood pressure, automated reading	2.78	7	4	8.9	0.65	1.1e-01	GPX1 MED8 MPP6 NEK4 PPA2 SLC5A11 TSNARE1
Leg predicted mass (left)	2.77	16	10	22.2	0.04	8.7e-01	BCDIN3D CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Leg fat-free mass (left)	2.76	16	10	22.2	0.04	8.7e-01	BCDIN3D CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Taking other prescription medications	2.75	3	1	2.2	0.00	1.0e+00	B3GALTL GPX1 RBM6
Neuroticism (Nagel 2018)	2.72	8	2	4.4	0.51	1.9e-01	B3GALTL CDH9 CELF2 CTC-498M16.2 GPX1 PLCL2 THEM6 TSNARE1
Illnesses of siblings	2.72	3	1	2.2	0.00	1.0e+00	RBL2 SLC5A11 ST3GAL3
Prospective memory result	2.70	1	0	0.0	0.00	1.0e+00	PLCL2
Allergy or Eczema	2.69	7	3	6.7	-0.68	9.6e-02	CDK2AP1 CTB-75G16.3 NEGR1 PLCL2 SULT1A1 SUOX TMED5
Arm predicted mass (right)	2.69	13	11	24.4	0.11	7.0e-01	CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Arm fat-free mass (right)	2.68	13	11	24.4	0.09	7.7e-01	CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX
Leg fat-free mass (right)	2.68	16	10	22.2	-0.14	5.9e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 IFT57 NEGR1 PPA2 PPP2R2D RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Vascular/heart problems diagnosed by doctor	2.68	9	1	2.2	-0.47	2.0e-01	MED8 NEGR1 NRBF2 RBL2 RSRC2 SLC5A11 SUOX TEX15 TSNARE1
Age when periods started (menarche)	2.66	7	5	11.1	0.65	1.1e-01	CTNNAL1 GPX1 MED8 NEGR1 NRBF2 RP11-7O11.3 SUOX
Leg predicted mass (right)	2.66	15	10	22.2	-0.16	5.6e-01	CDK2AP1 CTB-75G16.3 CTC-498M16.2 ELOVL7 GPX1 NEGR1 PPA2 PPP2R2D RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Past tobacco smoking	2.63	4	0	0.0	-1.00	4.6e-03	CELF2 RP11-7O11.3 SUOX WDR24
Depression (Nagel 2018)	2.61	2	0	0.0	0.00	1.0e+00	NRBF2 PLCL2
Hayfever, allergic rhinitis or eczema	2.60	6	1	2.2	-0.66	1.6e-01	CDK2AP1 NEGR1 PLCL2 SULT1A1 SUOX TMED5
Whole body water mass	2.60	14	11	24.4	-0.06	8.4e-01	CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Qualifications: CSEs or equivalent	2.58	2	0	0.0	0.00	1.0e+00	GPX1 ST3GAL3
Pain all over the body in last month	2.58	1	0	0.0	0.00	1.0e+00	GPX1
Hypertension (Self-reported)	2.58	7	1	2.2	0.62	1.4e-01	NEGR1 NRBF2 RBL2 SLC5A11 SUOX TEX15 TSNARE1
Whole body fat-free mass	2.58	14	11	24.4	-0.06	8.4e-01	CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Neuroticism	2.54	6	2	4.4	0.61	1.9e-01	B3GALTL CTC-498M16.2 GPX1 PLCL2 SIDT2 TSNARE1
High blood pressure	2.53	8	0	0.0	0.56	1.5e-01	NEGR1 NRBF2 RBL2 RSRC2 SLC5A11 SUOX TEX15 TSNARE1
Wheeze or whistling in the chest in last year	2.52	2	1	2.2	0.00	1.0e+00	GPX1 RBM6
Worry (Nagel 2018)	2.45	5	2	4.4	0.63	2.6e-01	AP001877.1 B3GALTL CTC-498M16.2 PLCL2 TSNARE1
Medication for pain relief, constipation, heartburn	2.45	4	1	2.2	-0.34	6.6e-01	CDK2AP1 GPX1 ST6GAL2 TEX15
Worrier / anxious feelings	2.44	4	1	2.2	0.65	3.5e-01	AP001877.1 B3GALTL NEK4 PLCL2
Ever smoked	2.44	2	0	0.0	0.00	1.0e+00	CDK2AP1 WDR24
Trunk fat-free mass	2.43	14	9	20.0	-0.10	7.3e-01	CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Trunk predicted mass	2.43	14	9	20.0	-0.10	7.1e-01	CDK2AP1 CTC-498M16.2 ELOVL7 GPX1 MEF2C NEGR1 PPA2 RBL2 RBM6 RSRC2 SLC5A11 SULT1A1 SUOX WDR24
Neuroticism score	2.41	4	2	4.4	0.99	1.3e-02	B3GALTL CELF2 GPX1 PLCL2
Ever highly irritable/argumentative for 2 days	2.40	2	1	2.2	0.00	1.0e+00	GPX1 RBM6
Cardiovascular Disease	2.39	6	2	4.4	-0.10	8.5e-01	MED8 NEGR1 RBL2 SIDT2 SULT1A1 TEX15
High blood pressure (siblings)	2.37	1	0	0.0	0.00	1.0e+00	SLC5A11
Bipolar Disorder or Schizophrenia	2.36	7	1	2.2	0.19	6.9e-01	CDK2AP1 ELOVL7 MED8 MPP6 NEK4 PLCL2 RP11-7O11.3
Average weekly fortified wine intake	2.36	1	0	0.0	0.00	1.0e+00	SLC5A11
Impedance of leg (left)	2.35	12	7	15.6	0.00	9.9e-01	AP001877.1 CDK2AP1 ELOVL7 GPX1 MEF2C NEGR1 NEK4 PPA2 RBL2 RBM6 SULT1A1 SUOX
Frequency of tiredness / lethargy in last 2 weeks	2.35	1	0	0.0	0.00	1.0e+00	GPX1
Father's age at death	2.32	2	0	0.0	0.00	1.0e+00	CDK2AP1 GPX1
Seen doctor (GP) for nerves, anxiety, tension or depression	2.32	2	1	2.2	0.00	1.0e+00	B3GALTL NEGR1
Schizophrenia (2018)	2.30	4	0	0.0	0.63	2.6e-01	CDK2AP1 ELOVL7 MED8 RP11-7O11.3
Schizophrenia (2014)	2.29	4	1	2.2	-0.30	7.0e-01	CDK2AP1 ELOVL7 PLCL2 TSNARE1
Impedance of leg (right)	2.29	11	5	11.1	-0.03	9.3e-01	AP001877.1 CTNNAL1 ELOVL7 GPX1 NEGR1 NEK4 PPA2 RBL2 RBM6 SULT1A1 SUOX
Allergy	2.29	3	2	4.4	0.00	1.0e+00	CDK2AP1 NEGR1 SUOX
Mouth/teeth dental problems	2.28	1	0	0.0	0.00	1.0e+00	ELOVL7
Irritable Bowel Disease (IBD)	2.26	3	2	4.4	0.00	1.0e+00	GPX1 RBM6 SULT1A1
Chronotype (morning person)	2.23	4	0	0.0	0.63	3.7e-01	CAMKMT DBN1 LIN52 SYPL2
Nervous feelings	2.23	3	0	0.0	0.00	1.0e+00	B3GALTL CTC-498M16.2 TSNARE1
Breastfed as a baby	2.23	1	0	0.0	0.00	1.0e+00	CDK2AP1
Financial situation satisfaction	2.23	1	1	2.2	0.00	1.0e+00	GPX1
Systolic Blood Pressure	2.22	10	6	13.3	0.45	1.9e-01	GPX1 MED8 MPP6 NEK4 PPP2R2D RSRC2 SIDT2 SLC5A11 ST6GAL2 TSNARE1
Mineral and other dietary supplements	2.22	1	0	0.0	0.00	1.0e+00	CTC-498M16.2
Exposure to tobacco smoke at home	2.21	1	0	0.0	0.00	1.0e+00	GPX1
Worry too long after embarrassment	2.20	3	0	0.0	0.00	1.0e+00	BCDIN3D DBN1 THEM6
Ulcerative Colitis (UC)	2.18	3	2	4.4	0.00	1.0e+00	GPX1 RBM6 SULT1A1
Forced expiratory volume in 1-second (FEV1), Best measure	2.17	6	3	6.7	-0.55	2.6e-01	GPX1 MFSD10 PLCL2 PPA2 RBM6 SUOX
Birth weight of first child	2.17	2	1	2.2	0.00	1.0e+00	PPA2 SUOX
Frequency of tenseness / restlessness in last 2 weeks	2.14	2	2	4.4	0.00	1.0e+00	B3GALTL GPX1
Medication: Paracetamol	2.13	2	0	0.0	0.00	1.0e+00	GPX1 TMED5
Comparative height size at age 10	2.13	12	9	20.0	-0.73	7.1e-03	BCDIN3D CAMKMT CDK2AP1 MED8 NEK4 RBL2 RBM6 RP11-7O11.3 RSRC2 SULT1A1 TMED5 WDR24
Forced expiratory volume in 1-second (FEV1)	2.12	7	2	4.4	-0.70	8.2e-02	BCDIN3D GPX1 MFSD10 PPA2 PPP2R2D RBM6 SUOX
Number of operations (self-reported)	2.11	2	0	0.0	0.00	1.0e+00	PPA2 RBM6
Cholesterol lowering medication	2.10	1	0	0.0	0.00	1.0e+00	SIDT2
Waist Hip Ratio (WHR)	2.08	8	4	8.9	0.36	3.8e-01	CDK2AP1 CTNNAL1 ELOVL7 GPX1 NEK4 PLCL2 RBL2 RSRC2
Standing height	2.08	16	11	24.4	-0.84	4.7e-05	CAMKMT CDK2AP1 GPX1 MED8 MFSD10 MPP6 NEK4 NRBF2 PPA2 PPP2R2D RBL2 RBM6 RSRC2 SIDT2 SLC5A11 WDR24
Age started oral contraceptive pill	2.06	2	0	0.0	0.00	1.0e+00	GPX1 IFT57
Reason for reducing amount of alcohol drunk: Health precaution	2.05	2	0	0.0	0.00	1.0e+00	CTC-498M16.2 SUOX
Medication: Paracetamol	2.05	2	0	0.0	0.00	1.0e+00	GPX1 TMED5
Frequency of depressed mood in last 2 weeks	2.03	2	0	0.0	0.00	1.0e+00	CELF2 PLCL2
Health satisfaction	2.03	3	0	0.0	0.00	1.0e+00	GPX1 MFSD10 TSNARE1
Loneliness, isolation	2.03	1	0	0.0	0.00	1.0e+00	GPX1
Hypothyroidism (self reported)	2.02	2	2	4.4	0.00	1.0e+00	SIDT2 SUOX
Medication: Co-codamol	2.02	2	0	0.0	0.00	1.0e+00	GPX1 RBM6
Sitting height	1.99	9	6	13.3	-0.97	2.1e-05	CAMKMT CDK2AP1 MED8 NEK4 PPA2 PPP2R2D RBL2 RSRC2 WDR24
Number of self-reported non-cancer illnesses	1.99	1	1	2.2	0.00	1.0e+00	NEGR1
Suffer from 'nerves'	1.95	3	0	0.0	0.00	1.0e+00	B3GALTL CTC-498M16.2 SULT1A1
Medication: Blood pressure	1.94	1	0	0.0	0.00	1.0e+00	NEK4
Respiratory disease	1.92	1	1	2.2	0.00	1.0e+00	SUOX
Crohns Disease (2017)	1.91	3	2	4.4	0.00	1.0e+00	GPX1 NEK4 SULT1A1
Ulcerative Colitis	1.91	2	1	2.2	0.00	1.0e+00	GPX1 RBM6
Number of full brothers	1.91	2	0	0.0	0.00	1.0e+00	GPX1 RBM6
Crohns Disease (2012)	1.90	2	2	4.4	0.00	1.0e+00	GPX1 SULT1A1
Medication for cholesterol	1.90	1	0	0.0	0.00	1.0e+00	RBL2
Guilty feelings	1.89	1	0	0.0	0.00	1.0e+00	GPX1
Bipolar Disorder (2018)	1.87	2	0	0.0	0.00	1.0e+00	MPP6 NEK4
Diabetes (self-reported)	1.87	2	0	0.0	0.00	1.0e+00	RBL2 ST6GAL2
Hypothyroidism/myxoedema (self-reported)	1.86	2	1	2.2	0.00	1.0e+00	SIDT2 SUOX
Height	1.85	20	14	31.1	-0.69	7.2e-04	AP001877.1 CAMKMT CDK2AP1 CTNNAL1 ELOVL7 GPX1 LIN52 MED8 MPP6 NEK4 NRBF2 PPA2 PPP2R2D RBL2 RBM6 RSRC2 SIDT2 SLC5A11 TMED5 WDR24
Blood White Count	1.84	12	9	20.0	0.64	2.4e-02	CKM CTC-498M16.2 GPX1 MED8 MFSD10 MPP6 NRBF2 PPA2 RBM6 SIDT2 SLC5A11 TEX15
Friendships satisfaction	1.84	1	0	0.0	0.00	1.0e+00	AP001877.1
Forced vital capacity (FVC), Best measure	1.83	8	2	4.4	-0.65	8.2e-02	BCDIN3D GPX1 MFSD10 PPA2 RBL2 RBM6 RSRC2 SUOX
Medication: Bendroflumethiazide	1.82	1	1	2.2	0.00	1.0e+00	TEX15
Long-standing illness, disability or infirmity	1.80	1	0	0.0	0.00	1.0e+00	NEGR1
Number of live births	1.76	1	0	0.0	0.00	1.0e+00	RBM6
Asthma (self-reported)	1.76	2	1	2.2	0.00	1.0e+00	CDK2AP1 SUOX
Forced vital capacity (FVC)	1.75	8	2	4.4	-0.99	4.4e-07	BCDIN3D GPX1 MFSD10 PPA2 PPP2R2D RBL2 RBM6 RSRC2
Illnesses of mother	1.75	1	0	0.0	0.00	1.0e+00	CTB-75G16.3
Asthma	1.73	1	1	2.2	0.00	1.0e+00	SUOX
Leg pain on walking	1.72	1	0	0.0	0.00	1.0e+00	GPX1
Medication: Simvastatin	1.71	1	0	0.0	0.00	1.0e+00	SIDT2
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.71	1	0	0.0	0.00	1.0e+00	PPA2
Diabetes diagnosed by doctor	1.70	1	0	0.0	0.00	1.0e+00	RBL2
Birth weight	1.69	1	0	0.0	0.00	1.0e+00	PPA2
Pulse rate, automated reading	1.69	4	2	4.4	0.58	4.2e-01	CTC-498M16.2 NEGR1 RBL2 SLC5A11
Lung FEV1/FVC ratio	1.67	7	4	8.9	0.12	8.0e-01	GPX1 LIN52 NEGR1 NRBF2 PPA2 SLC5A11 SUOX
High cholesterol (Self-reported)	1.67	1	1	2.2	0.00	1.0e+00	SIDT2
Ever had prostate specific antigen (PSA) test	1.67	1	0	0.0	0.00	1.0e+00	CTC-498M16.2
Type 2 Diabetes (T2D) (2018)	1.64	1	0	0.0	0.00	1.0e+00	RBL2
Neck or shoulder pain in last month	1.64	2	0	0.0	0.00	1.0e+00	GPX1 SUOX
HDL Cholesterol	1.61	2	1	2.2	0.00	1.0e+00	NRBF2 TMED5
Sensitivity / hurt feelings	1.61	1	0	0.0	0.00	1.0e+00	PLCL2
Hand grip strength (right)	1.61	5	2	4.4	-0.14	8.3e-01	NEK4 NPM3 RBL2 SLC5A11 SULT1A1
Ever used hormone-replacement therapy (HRT)	1.60	1	0	0.0	0.00	1.0e+00	BCDIN3D
Commuting to job workplace: Car/motor vehicle	1.60	1	0	0.0	0.00	1.0e+00	NEGR1
Medication: Atorvastatin	1.59	1	0	0.0	0.00	1.0e+00	SIDT2
Supplements: Zinc	1.58	1	0	0.0	0.00	1.0e+00	NRBF2
Mean time to correctly identify matches	1.56	1	0	0.0	0.00	1.0e+00	IFT57
Hayfever/allergic rhinitis (self-reported)	1.55	1	0	0.0	0.00	1.0e+00	SUOX
LDL Cholesterol	1.53	1	0	0.0	0.00	1.0e+00	SIDT2
Mouth/teeth dental problems: Mouth ulcers	1.51	1	0	0.0	0.00	1.0e+00	AP001877.1
Had other major operations	1.50	1	0	0.0	0.00	1.0e+00	PPA2
Medication: Cholesterol lowering	1.49	1	0	0.0	0.00	1.0e+00	SIDT2
Medication: Ventolin 100micrograms inhaler	1.49	1	0	0.0	0.00	1.0e+00	SUOX
Blood Eosinophil Count	1.47	7	7	15.6	-0.17	7.2e-01	CDK2AP1 CKM NEK4 PLCL2 SIDT2 SUOX TMED5
Handedness (chirality/laterality): Left-handed	1.46	1	0	0.0	0.00	1.0e+00	SULT1A1
Medication: Levothyroxine sodium	1.45	1	1	2.2	0.00	1.0e+00	SUOX
Hand grip strength (left)	1.40	3	2	4.4	0.00	1.0e+00	NEK4 NPM3 SLC5A11
Relative age of first facial hair	1.38	2	0	0.0	0.00	1.0e+00	MED8 NRBF2
Prostate Cancer	1.31	2	0	0.0	0.00	1.0e+00	GPX1 PPA2
Blood Red Count	1.30	13	10	22.2	0.28	3.6e-01	AP001877.1 CAMKMT CHST10 CKM CTC-498M16.2 LIN52 MED8 MEF2C NRBF2 PLCL2 SULT1A1 SUOX TMED5
Headache pain in last month	1.30	1	0	0.0	0.00	1.0e+00	SUOX
Breast Cancer	1.24	1	0	0.0	0.00	1.0e+00	GPX1
Primary Biliary Cirrhosis	1.22	1	0	0.0	0.00	1.0e+00	PLCL2
Lung FVC	1.21	5	3	6.7	0.42	4.8e-01	BCDIN3D GPX1 MFSD10 NRBF2 SUOX
Pulse rate	1.21	1	0	0.0	0.00	1.0e+00	RBL2
Heel T-Score	0.86	4	2	4.4	0.72	2.8e-01	CDK2AP1 NEGR1 NEK4 SLC5A11
Hair Pigment	0.14	2	1	2.2	0.00	1.0e+00	CDK2AP1 SUOX

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Cerebellar Hemisphere	9	0.60	2.4
GTEx	Colon Sigmoid	9	0.62	2.4
GTEx	Stomach	12	0.83	2.4
GTEx	Adipose Visceral Omentum	11	0.54	2.3
GTEx	Brain Cerebellum	10	0.50	2.3
GTEx	Brain Frontal Cortex BA9	5	0.54	2.3
GTEx	Brain Nucleus accumbens basal ganglia	3	0.35	2.3
GTEx	Breast Mammary Tissue	13	0.66	2.3
GTEx	Breast Mammary Tissue (Female)	12	0.73	2.3
GTEx	Esophagus Gastroesophageal Junction	7	0.48	2.3
GTEx	Esophagus Muscularis	22	0.68	2.3
GTEx	Heart Atrial Appendage	9	0.57	2.3
GTEx	Muscle Skeletal	18	0.62	2.3
GTEx	Ovary	5	0.55	2.3
GTEx	Pancreas	14	0.86	2.3
GTEx	Skin Not Sun Exposed Suprapubic	16	0.65	2.3
GTEx	Spleen	7	0.50	2.3
GTEx	Testis	14	0.44	2.3
GTEx	Adipose Subcutaneous	17	0.49	2.2
GTEx	Artery Aorta	17	0.57	2.2
GTEx	Artery Coronary	2	0.17	2.2
GTEx	Artery Tibial	26	0.69	2.2
GTEx	Brain Caudate basal ganglia	5	0.54	2.2
GTEx	Brain Cortex	7	0.68	2.2
GTEx	Brain Hippocampus	2	0.38	2.2
GTEx	Brain Putamen basal ganglia	3	0.48	2.2
GTEx	Cells EBV-transformed lymphocytes	5	0.35	2.2
GTEx	Cells Transformed fibroblasts	24	0.57	2.2
GTEx	Colon Transverse	12	0.58	2.2
GTEx	Esophagus Mucosa	19	0.57	2.2
GTEx	Heart Left Ventricle	8	0.52	2.2
GTEx	Liver	3	0.42	2.2
GTEx	Lung	15	0.52	2.2
GTEx	Nerve Tibial	24	0.56	2.2
GTEx	Pituitary	4	0.36	2.2
GTEx	Prostate	5	0.60	2.2
GTEx	Skin Sun Exposed Lower leg	18	0.49	2.2
GTEx	Small Intestine Terminal Ileum	4	0.87	2.2
GTEx	Thyroid	19	0.48	2.2
GTEx	Vagina	5	0.79	2.2
ROSMAP	Brain Pre-frontal Cortex	19	0.43	2.2
The Cancer Genome Atlas	Glioblastoma Multiforme	5	0.49	2.2
GTEx	Breast Mammary Tissue (Male)	3	0.25	2.1
GTEx	Uterus	1	0.18	2.1
GTEx	Whole Blood	6	0.30	2.1
METSIM	Adipose	17	0.37	2.1
CommonMind	Brain Pre-frontal Cortex	16	0.30	2.1
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	7	0.42	2.1
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	5	0.46	2.1
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	12	0.44	2.1
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	8	0.39	2.1
The Cancer Genome Atlas	Brain Lower Grade Glioma	16	0.37	2.1
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	8	0.72	2.1
The Cancer Genome Atlas	Lung Adenocarcinoma	14	0.48	2.1
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	11	0.66	2.1
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	7	0.53	2.1
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.29	2.1
The Cancer Genome Atlas	Soft Tissue Sarcoma	2	0.19	2.1
The Cancer Genome Atlas	Stomach Adenocarcinoma	6	0.36	2.1
GTEx	Adrenal Gland	4	0.27	2.0
GTEx	Brain Hypothalamus	1	0.17	2.0
NTR	Blood	5	0.21	2.0
YFS	Blood	14	0.30	2.0
The Cancer Genome Atlas	Breast Invasive Carcinoma	14	0.32	2.0
The Cancer Genome Atlas	Colon Adenocarcinoma	8	0.39	2.0
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	14	0.34	2.0
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	10	0.40	2.0
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	6	0.38	2.0
The Cancer Genome Atlas	Prostate Adenocarcinoma	19	0.41	2.0
The Cancer Genome Atlas	Skin Cutaneous Melanoma	2	0.37	2.0
The Cancer Genome Atlas	Testicular Germ Cell Tumors	4	0.31	2.0
The Cancer Genome Atlas	Thyroid Carcinoma	17	0.33	2.0
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.39	2.0
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.15	1.9